MedTrace Logo

Role of FDG PET, Immune and Hypoxic Marker in NSCLC

NCT02519062 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2020-10-01

No results posted yet for this study

Summary

This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

OTHER

No intervention

This is a retrospective study

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Egesta Lopci, MD · Humanitas Clinical and Research Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02519062 on ClinicalTrials.gov